FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024004047> ?p ?o ?g. }

• W2024004047 endingPage "147" @default.
• W2024004047 startingPage "142" @default.
• W2024004047 abstract "This prospective study evaluated the cardiovascular and antiarrhythmic effects of esmolol, an intravenous β-blocker with an extremely short half-life. Twenty patients (aged 2 to 16 years) underwent diagnostic electrophysiologic studies at rest and during β-blockade induced with esmolol. An initial dose of 600 μg/kg was infused for 2 minutes and followed by an infusion of 200 μg/kg per minute. The dosage was increased by 50 to 100 μg/kg per minute every 5 to 10 minutes until a reduction of >10% in either heart rate or mean blood pressure was seen. The dosage required to achieve β-blockade ranged from 300 to 1000 μg/kg per minute (mean 550 μg/kg per minute). Electrophysiologic effects included a decrease in the rate of sinoatrial node discharge and delay in conduction through the atrioventricular node. There was no effect on His-Purkinje conduction. Atrial and ventricular effective refractory periods were unchanged. In six patients with supraventricular tachycardia, esmolol prevented induction of tachycardia in four and slowed the rate of the tachycardia in two. In four patients with ventricular tachycardia, clinical findings were improved in three and unchanged in one. Heart rate and blood pressure returned to near baseline values 10 minutes after the esmolol infusion was stopped. Adverse ventricular electrophysiologic effects were observed in two patients with biopsy evidence of myocarditis. No other adverse effects were seen. We conclude that the effects of esmolol in children are similar to those of other β-blockers and that it is useful in the evaluation and management of pediatric tachyarrhythmias. The weight-adjusted dosage required to induce β-blockade in children is larger than the adult dosage, and the effects of esmolol dissipate rapidly. This prospective study evaluated the cardiovascular and antiarrhythmic effects of esmolol, an intravenous β-blocker with an extremely short half-life. Twenty patients (aged 2 to 16 years) underwent diagnostic electrophysiologic studies at rest and during β-blockade induced with esmolol. An initial dose of 600 μg/kg was infused for 2 minutes and followed by an infusion of 200 μg/kg per minute. The dosage was increased by 50 to 100 μg/kg per minute every 5 to 10 minutes until a reduction of >10% in either heart rate or mean blood pressure was seen. The dosage required to achieve β-blockade ranged from 300 to 1000 μg/kg per minute (mean 550 μg/kg per minute). Electrophysiologic effects included a decrease in the rate of sinoatrial node discharge and delay in conduction through the atrioventricular node. There was no effect on His-Purkinje conduction. Atrial and ventricular effective refractory periods were unchanged. In six patients with supraventricular tachycardia, esmolol prevented induction of tachycardia in four and slowed the rate of the tachycardia in two. In four patients with ventricular tachycardia, clinical findings were improved in three and unchanged in one. Heart rate and blood pressure returned to near baseline values 10 minutes after the esmolol infusion was stopped. Adverse ventricular electrophysiologic effects were observed in two patients with biopsy evidence of myocarditis. No other adverse effects were seen. We conclude that the effects of esmolol in children are similar to those of other β-blockers and that it is useful in the evaluation and management of pediatric tachyarrhythmias. The weight-adjusted dosage required to induce β-blockade in children is larger than the adult dosage, and the effects of esmolol dissipate rapidly." @default.
• W2024004047 created "2016-06-24" @default.
• W2024004047 creator A5007670031 @default.
• W2024004047 creator A5068623216 @default.
• W2024004047 creator A5085113371 @default.
• W2024004047 date "1991-07-01" @default.
• W2024004047 modified "2023-09-26" @default.
• W2024004047 title "Cardiovascular and antiarrhythmic effects of esmolol in children" @default.
• W2024004047 cites W193253733 @default.
• W2024004047 cites W1968308007 @default.
• W2024004047 cites W1981199592 @default.
• W2024004047 cites W1989559148 @default.
• W2024004047 cites W1994678366 @default.
• W2024004047 cites W2007562158 @default.
• W2024004047 cites W2007662353 @default.
• W2024004047 cites W2021317099 @default.
• W2024004047 cites W2025162362 @default.
• W2024004047 cites W2028947924 @default.
• W2024004047 cites W2040006738 @default.
• W2024004047 cites W2051721480 @default.
• W2024004047 cites W2058417686 @default.
• W2024004047 cites W2069288227 @default.
• W2024004047 cites W2073986408 @default.
• W2024004047 cites W2079922025 @default.
• W2024004047 cites W2081935179 @default.
• W2024004047 cites W2089806972 @default.
• W2024004047 cites W2091010402 @default.
• W2024004047 cites W2094760741 @default.
• W2024004047 cites W2104166566 @default.
• W2024004047 cites W2109451590 @default.
• W2024004047 cites W2156401481 @default.
• W2024004047 cites W4246625370 @default.
• W2024004047 doi "https://doi.org/10.1016/s0022-3476(05)81055-8" @default.
• W2024004047 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1676729" @default.
• W2024004047 hasPublicationYear "1991" @default.
• W2024004047 type Work @default.
• W2024004047 sameAs 2024004047 @default.
• W2024004047 citedByCount "34" @default.
• W2024004047 countsByYear W20240040472012 @default.
• W2024004047 countsByYear W20240040472013 @default.
• W2024004047 countsByYear W20240040472014 @default.
• W2024004047 countsByYear W20240040472015 @default.
• W2024004047 countsByYear W20240040472016 @default.
• W2024004047 countsByYear W20240040472017 @default.
• W2024004047 countsByYear W20240040472018 @default.
• W2024004047 countsByYear W20240040472019 @default.
• W2024004047 countsByYear W20240040472020 @default.
• W2024004047 countsByYear W20240040472021 @default.
• W2024004047 crossrefType "journal-article" @default.
• W2024004047 hasAuthorship W2024004047A5007670031 @default.
• W2024004047 hasAuthorship W2024004047A5068623216 @default.
• W2024004047 hasAuthorship W2024004047A5085113371 @default.
• W2024004047 hasConcept C126322002 @default.
• W2024004047 hasConcept C164705383 @default.
• W2024004047 hasConcept C197934379 @default.
• W2024004047 hasConcept C2776024998 @default.
• W2024004047 hasConcept C2776934708 @default.
• W2024004047 hasConcept C2777953023 @default.
• W2024004047 hasConcept C2780283014 @default.
• W2024004047 hasConcept C2780996683 @default.
• W2024004047 hasConcept C42219234 @default.
• W2024004047 hasConcept C71924100 @default.
• W2024004047 hasConcept C84393581 @default.
• W2024004047 hasConceptScore W2024004047C126322002 @default.
• W2024004047 hasConceptScore W2024004047C164705383 @default.
• W2024004047 hasConceptScore W2024004047C197934379 @default.
• W2024004047 hasConceptScore W2024004047C2776024998 @default.
• W2024004047 hasConceptScore W2024004047C2776934708 @default.
• W2024004047 hasConceptScore W2024004047C2777953023 @default.
• W2024004047 hasConceptScore W2024004047C2780283014 @default.
• W2024004047 hasConceptScore W2024004047C2780996683 @default.
• W2024004047 hasConceptScore W2024004047C42219234 @default.
• W2024004047 hasConceptScore W2024004047C71924100 @default.
• W2024004047 hasConceptScore W2024004047C84393581 @default.
• W2024004047 hasIssue "1" @default.
• W2024004047 hasLocation W20240040471 @default.
• W2024004047 hasLocation W20240040472 @default.
• W2024004047 hasOpenAccess W2024004047 @default.
• W2024004047 hasPrimaryLocation W20240040471 @default.
• W2024004047 hasRelatedWork W1963592535 @default.
• W2024004047 hasRelatedWork W1987426280 @default.
• W2024004047 hasRelatedWork W2007717419 @default.
• W2024004047 hasRelatedWork W2066607298 @default.
• W2024004047 hasRelatedWork W2169102761 @default.
• W2024004047 hasRelatedWork W2336466303 @default.
• W2024004047 hasRelatedWork W2353557876 @default.
• W2024004047 hasRelatedWork W2366401541 @default.
• W2024004047 hasRelatedWork W2423177691 @default.
• W2024004047 hasRelatedWork W2186972882 @default.
• W2024004047 hasVolume "119" @default.
• W2024004047 isParatext "false" @default.
• W2024004047 isRetracted "false" @default.
• W2024004047 magId "2024004047" @default.
• W2024004047 workType "article" @default.